00:02No cuts to healthcare but an increase in resources which represents a result
00:08anything but a given. With these words, Economy Minister Giancarlo Giorgetti
00:14responded to criticism during the hearing on the 2027 budget, claiming the funding
00:20for the National Health Service, from additional funds for staff and emergency rooms
00:26up to the measures for drugs, medical devices and non-self-sufficient elderly people. But alongside
00:33In defense of the accounts, the Treasury Secretary sent a clear warning to the regions.
00:39The resources allocated must be matched by much more efficient management, capable of translating
00:46concretely the funds in real services for citizens.
00:51There are 5.6 million people who give up on treatment, while in 2025 families have
00:58spent 42.4 billion from their own pockets. These are the key figures from the poverty and resources report.
01:062026 by Caritas Italiana, which photographs a constant growth of inequalities in access
01:13to health. The first national survey of the Caritas network's clinics records 110
01:21facilities in 89 dioceses, where over 30 thousand people were assisted, half of them Italian, with
01:29a 69% increase in health fragility in 10 years and a boom in cases of depression.
01:37Faced with this scenario, the organization calls for more resources for the National Health Service
01:43National, accessible territorial services and a stable connection with the homes of the
01:49community.
01:51An indispensable pillar for the present and future of Italian healthcare, thus the
01:57Health Minister Orazio Schillaci defined hospital pharmacists while speaking
02:03at the 47th SIFO national congress, which took place last week at the
02:09100 conferences at La Nuvola di Roma. Not just distribution professionals, he continued.
02:15the minister, but real clinical and economic decision makers, whose contribution is strategic
02:22in the management of innovative drugs, biosimilars and in the sustainability of spending
02:28public. Also on the table are the challenges for the future, from young specialists to the need
02:34estimated at almost 500 new units dedicated to hospital pharmacies, Schillaci concluded.
02:43Therapies exist, but too often they are not prescribed. This is the picture that emerges from a study.
02:50Presented at the 67th Congress of the Italian Society of Nephrology in Sorrento. Over 4,500
02:57Patients, followed in 30 Italian centers, were involved in the research. The data highlight
03:05high therapeutic inertia. This reaches 96% in patients with chronic kidney disease and diabetes.
03:13Type 2 due to the failure to use the Renone end-product in eligible subjects. A delay in treatment which,
03:20According to experts, it can compromise the protection of the kidneys and the cardiovascular system.
03:26The appeal of specialists, therefore, is clear. Overcoming prescriptive resistance,
03:32strengthen collaboration between family doctors and specialists and make it routine
03:38Tests to assess renal function and albuminuria. The goal is to diagnose
03:45earlier, timely therapies to slow down the progression of diseases and avoid,
03:51when possible, dialysis. A little-known disease,
03:57Difficult to diagnose and still seeking full recognition of rights. It is hypoparathyroidism.
04:05At the center of the first appointment of the Bari hip-paraturra. The series of events is organized
04:12from the rare disease observatory OMAR in collaboration with the Association for APODV patients and the
04:20Ascendis Pharma's non-conditioning contribution. Tingling, muscle cramps, and chronic fatigue.
04:27are some of the often underestimated symptoms of this endocrine pathology linked to a
04:33insufficient production of parathyroid hormone, which is essential for regulating calcium and phosphorus
04:40in the body. But there's also the issue of rights. Hypoparathyroidism, according to experts,
04:46It is not yet formally classified as a rare disease, often making it more complex
04:52access to certain protections. To address these challenges, the Rare Disease Observatory
04:58has created a free, online guide to rights to guide patients and caregivers
05:04between disability, exemptions, and concessions. The Italian Medicines Agency has approved
05:13reimbursement also for adults of Selumetinib, a drug indicated for the treatment
05:20symptomatic and inoperable plexiform neurofibromas. NF1 is a genetic disease.
05:29rare and progressive, up to 50% of patients may develop plexiform neurofibromas, tumors
05:37benign that can affect the nerves, brain and spinal cord, causing pain, deformity
05:43and muscle weakness. The decision is based on the results of the international study of
05:49phase 3 COMET, conducted on 145 adult patients in 13 countries, which showed a response
05:57treatment significantly superior to placebo.
06:03From grocery shopping to scientific research, the solidarity of Coop Alleanza 3.0 members
06:10becomes an investment in cancer prevention. In Bologna it was delivered to the Institute
06:16Ramazzini made a contribution of 18,965 euros, raised thanks to points donated by members from the provinces
06:25of Bologna and Ferrara. The Somma will fund a scholarship for a young researcher
06:31of the Cesare Maltoni Cancer Research Center, engaged in the study of the possible carcinogenicity
06:38of pesticides and their mixtures. The aim is to further investigate the effects of these substances.
06:44on human health and identify the mechanisms of their toxicity. Preventing tomorrow's tumors,
06:51investing today in the knowledge of environmental risks, this is therefore the challenge of
06:56independent research, also supported by citizen participation.
Commenti